Sionna Therapeutics Investors Face 90% Loss After Failed Clinical Trial

The PreciSION CF trial for SION-719, a candidate designed to treat cystic fibrosis, yielded a placebo-adjusted sweat chloride change of just -1.0 mmol/L with a p-value of 0.7. Following these results, Sionna Therapeutics abandoned the drug as an add-on therapy. This development stands in stark contrast to the company's previous disclosures in its FY2025 Form 10-K, where it emphasized a heavy reliance on the success of its nucleotide binding domain 1 (NBD1) stabilizers.

Despite the clinical failure, the company maintains a stable financial position, reporting approximately $268.3 million in cash and marketable securities as of June 30, 2026. The investigation led by Joseph E. Levi seeks to determine if management adequately disclosed the regulatory and clinical hazards associated with the SION-719 program prior to the data readout. Investors who acquired shares during the period affected by these disclosures are now being reviewed for potential recovery claims.